Amygdala

Dec 03, 2019

Imaging Reveals Pathways Behind Depression

Nov 25, 2019

Prenatal Opioid Exposure May Alter Brain Function in Babies

Nov 18, 2019

Amygdala Neurosciences Announces $5.6M Financing and Dr. Mack Mitchell's Expanded Role as CMO

Oct 21, 2019

Animal Study Shows How Stress and Mother's Abuse Affects Infant Brain

Oct 21, 2019

Amygdala Neurosciences Awarded $1.35 million NIH Grant to Conduct Long Term, Phase 3 Enabling, Toxicology Studies

Oct 17, 2019

Amygdala Neurosciences Announces Dosing of the First Patient in the NIH Funded Phase 2 Proof-Of-Concept study of ANS-6637 for the Treatment of Alcohol Use Disorder

Mar 28, 2019

Amygdala Neurosciences Announces Dosing the First Patients in the $12.4 Million NIH HEAL Initiative Funded SEARCH Program of Clinical Studies with ANS-6637

Sep 19, 2018

Amygdala Neurosciences Announces the $12.4 Million HEAL Initiative Sponsored SEARCH (Safety and Efficacy of ANS-6637 to Reduce Drug Craving and Harm in People with Opioid Use Disorder) Program of Phase 2 Clinical Studies

Aug 28, 2018

Boys Town National Research Hospital Helps Target Behavioral Interventions for Aggressive Youth

May 29, 2018

Scientists show how brain circuit generates anxiety

Aug 01, 2017

Amygdala Neurosciences Initiates Phase 1b Clinical Study of ANS-6637, the First-In-Class Selective ALDH2 Inhibitor in Development as a Treatment for Substance Use Disorder